Cargando…
Adiponectin and Lipoprotein Particle Size
OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cr...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699707/ https://www.ncbi.nlm.nih.gov/pubmed/19389813 http://dx.doi.org/10.2337/dc09-0084 |
_version_ | 1782168521021587456 |
---|---|
author | Weiss, Ram Otvos, James D. Flyvbjerg, Allan Miserez, Andre R. Frystyk, Jan Sinnreich, Ronit Kark, Jeremy D. |
author_facet | Weiss, Ram Otvos, James D. Flyvbjerg, Allan Miserez, Andre R. Frystyk, Jan Sinnreich, Ronit Kark, Jeremy D. |
author_sort | Weiss, Ram |
collection | PubMed |
description | OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study was conducted. Lipoprotein particle size was assessed using proton nuclear magnetic resonance. RESULTS: In multivariable linear regression models that included sex, BMI, waist circumference, homeostasis model assessment of insulin resistance, and leptin, adiponectin was associated with mean LDL size (standardized regression coefficient B = 0.20; P < 0.001), VLDL size (B = −0.12; P < 0.001), and HDL size (B = 0.06; P = 0.013). Adiponectin was inversely related to large VLDL (P < 0.001) but positively to small VLDL (P = 0.02), inversely related to small LDL (P < 0.006) but positively to large LDL (P < 0.001), and positively related to large HDL (P < 0.001) subclass concentrations. CONCLUSIONS: Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity. |
format | Text |
id | pubmed-2699707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-26997072010-07-01 Adiponectin and Lipoprotein Particle Size Weiss, Ram Otvos, James D. Flyvbjerg, Allan Miserez, Andre R. Frystyk, Jan Sinnreich, Ronit Kark, Jeremy D. Diabetes Care Original Research OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study was conducted. Lipoprotein particle size was assessed using proton nuclear magnetic resonance. RESULTS: In multivariable linear regression models that included sex, BMI, waist circumference, homeostasis model assessment of insulin resistance, and leptin, adiponectin was associated with mean LDL size (standardized regression coefficient B = 0.20; P < 0.001), VLDL size (B = −0.12; P < 0.001), and HDL size (B = 0.06; P = 0.013). Adiponectin was inversely related to large VLDL (P < 0.001) but positively to small VLDL (P = 0.02), inversely related to small LDL (P < 0.006) but positively to large LDL (P < 0.001), and positively related to large HDL (P < 0.001) subclass concentrations. CONCLUSIONS: Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity. American Diabetes Association 2009-07 2009-04-23 /pmc/articles/PMC2699707/ /pubmed/19389813 http://dx.doi.org/10.2337/dc09-0084 Text en © 2009 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details. |
spellingShingle | Original Research Weiss, Ram Otvos, James D. Flyvbjerg, Allan Miserez, Andre R. Frystyk, Jan Sinnreich, Ronit Kark, Jeremy D. Adiponectin and Lipoprotein Particle Size |
title | Adiponectin and Lipoprotein Particle Size |
title_full | Adiponectin and Lipoprotein Particle Size |
title_fullStr | Adiponectin and Lipoprotein Particle Size |
title_full_unstemmed | Adiponectin and Lipoprotein Particle Size |
title_short | Adiponectin and Lipoprotein Particle Size |
title_sort | adiponectin and lipoprotein particle size |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699707/ https://www.ncbi.nlm.nih.gov/pubmed/19389813 http://dx.doi.org/10.2337/dc09-0084 |
work_keys_str_mv | AT weissram adiponectinandlipoproteinparticlesize AT otvosjamesd adiponectinandlipoproteinparticlesize AT flyvbjergallan adiponectinandlipoproteinparticlesize AT miserezandrer adiponectinandlipoproteinparticlesize AT frystykjan adiponectinandlipoproteinparticlesize AT sinnreichronit adiponectinandlipoproteinparticlesize AT karkjeremyd adiponectinandlipoproteinparticlesize |